The U.S. Food and Drug Administration approved Agios Pharmaceuticals Inc.’s oral PK activator Pyrukynd (mitapivat) as the first approved disease-modifying therapy for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.